Catalyst
Slingshot members are tracking this event:
FDA designates Kite Pharma's (KITE) KTE-C19 a Breakthrough Therapy for the treatment of Refractory Diffuse Large B cell Lymphoma, Primary Mediastinal B Cell Lymphoma and Transformed Follicular Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| KITE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 07, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Primary Mediastinal B Cell Lymphoma, Refractory Diffuse Large B Cell Lymphoma, Kte-c19, Breakthrough Therapy Designation, Transformed Follicular Lymphoma, Zuma-1
